Department of Rheumatology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
J Clin Lab Anal. 2022 Jul;36(7):e24472. doi: 10.1002/jcla.24472. Epub 2022 May 27.
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) facilitates CD4 T-cell differentiation, immune response, inflammation, and osteoclastogenesis. This study aimed to explore the relation between MALT1 and treatment efficacy to tumor necrosis factor inhibitor (TNFi) in ankylosing spondylitis (AS) patients.
This study recruited 73 AS patients underwent adalimumab treatment. Peripheral blood mononuclear cell (PBMC) was obtained at Week (W) 0, W4, W8, and W12 after treatment initiation; then, MALT1 was measured using RT-qPCR. Furthermore, PBMC and serum at W0 were proposed to flow cytometry and ELISA for Th1 cells, Th17 cells, IFN-γ, and IL-17A levels measurement. Besides, 20 osteoarthritis patients and 20 healthy controls (HCs) were enrolled to detect MALT1.
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 expression was higher in AS patients compared with HCs (p < 0.001) and osteoarthritis patients (p < 0.001). Besides, MALT1 expression was positively linked with CRP (p = 0.002), BASDAI (p = 0.026), PGADA (p = 0.040), ASDAS (p = 0.028), Th17 cells (p = 0.020), and IL-17A (p = 0.017) in AS patients, but did not relate to other clinical features, Th1 cells or IFN-γ (all p>0.050). MALT1 was decreased along with treatment only in AS patients with ASAS40 response (p < 0.001), but not in those without ASAS40 response (p = 0.064). Notably, MALT1 expression was of no difference at W0 (p = 0.328), W4 (p = 0.280), and W8 (p = 0.080), but lower at W12 (p = 0.028) in AS patients with ASAS40 response compared with those without ASAS40 response.
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 positively correlates with Th17 cells, inflammatory, and activity degree; meanwhile, its decrement along with treatment reflects the response to TNF inhibitor in AS patients.
黏膜相关淋巴组织淋巴瘤易位蛋白 1(MALT1)有助于 CD4 T 细胞分化、免疫应答、炎症和破骨细胞生成。本研究旨在探讨 MALT1 与肿瘤坏死因子抑制剂(TNFi)在强直性脊柱炎(AS)患者中的疗效关系。
本研究纳入了 73 名接受阿达木单抗治疗的 AS 患者。在治疗开始后的第 0、4、8 和 12 周时采集外周血单个核细胞(PBMC),并采用 RT-qPCR 检测 MALT1 的表达水平。此外,在第 0 周时还采集 PBMC 和血清,采用流式细胞术和 ELISA 检测 Th1 细胞、Th17 细胞、IFN-γ和 IL-17A 水平。另外,还纳入了 20 名骨关节炎患者和 20 名健康对照者(HCs)检测 MALT1 的表达。
与 HCs(p<0.001)和骨关节炎患者(p<0.001)相比,AS 患者的 MALT1 表达水平更高。此外,MALT1 表达与 CRP(p=0.002)、BASDAI(p=0.026)、PGADA(p=0.040)、ASDAS(p=0.028)、Th17 细胞(p=0.020)和 IL-17A(p=0.017)呈正相关,但与其他临床特征、Th1 细胞或 IFN-γ无相关性(均 p>0.050)。只有在 ASAS40 应答的 AS 患者中,MALT1 才随治疗而降低(p<0.001),而在无 ASAS40 应答的患者中则无变化(p=0.064)。值得注意的是,在 ASAS40 应答的 AS 患者中,MALT1 在第 0 周(p=0.328)、第 4 周(p=0.280)和第 8 周(p=0.080)时的表达无差异,但在第 12 周时(p=0.028)的表达低于无 ASAS40 应答的患者。
MALT1 与 Th17 细胞、炎症和活动程度呈正相关,其随治疗而降低反映了 AS 患者对 TNF 抑制剂的反应。